Examkin

Question

Difficulty: Very hardGynecologic Infections

A 36-year-old woman comes to the clinic for evaluation of severe vulvar itching and vaginal burning that began 5 days ago. Over the past year, she has had four similar episodes. Each prior episode was treated with a single dose of oral fluconazole, which provided only transient partial relief before her symptoms recurred. Her medical history includes type 2 diabetes mellitus. Current medications include metformin and sitagliptin, though she admits to frequently missing doses. Her most recent hemoglobin A1c is 9.4%. Vital signs are temperature 37.0°C (98.6°F), blood pressure 122/78 mmHg, heart rate 78/min, and respiratory rate 14/min. Pelvic examination demonstrates pronounced vulvar erythema and edema with visible excoriations. A moderate amount of thick, white, adherent discharge is present in the vaginal vault. The cervix is visually normal with no bleeding or discharge from the external os, and bimanual examination is unremarkable with no cervical motion tenderness. Vaginal pH is 4.3. Wet mount microscopy with 10% potassium hydroxide preparation reveals numerous small budding yeast cells but is notably negative for pseudohyphae. Which of the following is the most appropriate next step in management for this patient?

  1. A
    Weekly oral fluconazole therapy for 6 months
  2. B
    Oral metronidazole therapy
  3. Intravaginal boric acid therapyAnswer
  4. D
    Intramuscular ceftriaxone and oral doxycycline
  5. E
    Intravenous micafungin therapy

Answer

Intravaginal boric acid therapy
The correct answer is intravaginal boric acid therapy. This patient has recurrent vulvovaginal candidiasis (RVVC), defined as four or more episodes in a single year. Her poorly controlled diabetes mellitus is a significant risk factor for atypical fungal infections. While the vast majority of RVVC is caused by Candida albicans, her failure to fully respond to multiple prior courses of fluconazole and the specific microscopic finding of budding yeast without pseudohyphae strongly point to a non-albicans species, most commonly Candida glabrata. Unlike C. albicans, C. glabrata lacks the ability to form pseudohyphae and has high rates of intrinsic resistance to azole antifungals. Consequently, the first-line recommended treatment for azole-refractory C. glabrata vulvovaginitis is intravaginal boric acid therapy for 14 days.

Step-by-Step Solution

1
Analyze the patient's presenting symptoms and clinical history.
The patient has recurrent vulvovaginitis (4 or more episodes per year) in the setting of poorly controlled diabetes mellitus.
To identify the clinical syndrome and recognize risk factors for infections with atypical pathogens.
2
Evaluate the response to prior therapies and laboratory findings.
The patient failed multiple courses of fluconazole, and the wet mount shows budding yeast but notably lacks pseudohyphae.
To determine the specific etiology. The absence of pseudohyphae and clinical azole resistance strongly point to a non-albicans species, specifically Candida glabrata.
3
Select the most appropriate evidence-based therapy.
Intravaginal boric acid is selected.
Boric acid is the recommended first-line treatment for azole-refractory, non-albicans Candida vulvovaginitis.

Key Concept

Recurrent, fluconazole-refractory vulvovaginal candidiasis showing budding yeast without pseudohyphae is typically caused by Candida glabrata, which requires treatment with intravaginal boric acid.
Rate this question

Topics

Gynecologic Infections

More questions from this topic